RPT-FACTBOX-Drug company Biovail's legal woes

(Refiles to fix spelling of 'drug' in headline)

Feb 1 (Reuters) - Biovail Corp (BVF.TO) (BVF.N) said on Friday that it is being investigated by a U.S. Federal grand jury concerning the 2003 commercial launch of its Cardizem LA heart drug. Following is a list of key dates of the drug company's legal issues:

Feb. 1, 2008 - Biovail faces U.S. grand jury probe over marketing of Cardizem heart drug

Dec. 11, 2007 - Biovail settles U.S. shareholder lawsuit that stretched back more than four years

Sept. 11, 2007 - Biovail settles with Banc of America Securities analyst

May 18, 2007 - Ontario Securities Commission approves deal that settles trading disclosure allegations against company founder Eugene Melnyk

Feb. 22, 2006 - Biovail files lawsuit alleging stock market manipulation scheme

Nov. 20, 2003 - Biovail confirms informal inquiry by U.S. Securities and Exchange Commission into accounting and financial reporting practices

Aug. 22, 2003 - Biovail initially receives administrative inquiry from U.S. Office of the Inspector General into marketing programs related to Cardizem

($1=$0.99 Canadian) (Reporting by Scott Anderson; Editing by Rob Wilson)